Dr. Reddy's Laboratories (RDY) reported fiscal Q3 earnings Thursday of $0.20 per diluted share, up from $0.19 a year earlier.
Three analysts polled by FactSet expected $0.21.
Revenue for the quarter ended Dec. 31 was $977 million, compared with $843 million a year earlier.
Analysts surveyed by FactSet expected $950.5 million.
RDY shares were down 5.2% in recent trading.
Price: 14.31, Change: -0.79, Percent Change: -5.20